Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D07ALX
|
|||
| Drug Name |
Sirolimus
|
|||
| Synonyms |
Rapammune; Sirolimus; Rapamycin; I2190A; 53123-88-9; (-)-Rapamycin; Wy 090217; SIIA 9268A; Rapamune; I-2190A; AY-22989; RAPA; NSC 226080; I 2190A; AY 22989; Rapamycin (Sirolimus); WY-090217; Antibiotic AY 22989; UNII-W36ZG6FT64; SILA 9268A; CHEBI:9168; CCRIS 9024; W36ZG6FT64; HSDB 7284; C51H79NO13; DE-109; NCGC00021305-05; DSSTox_CID_3582; DSSTox_RID_77091; DSSTox_GSID_23582; Supralimus; Sirolimus
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Lymphangioleiomyomatosis [ICD-11: CB07] | Approved | [1] | |
| Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] | Phase 2 | [2] | ||
| Therapeutic Class |
Antiviral Agents
|
|||
| Structure |
 |
Download2D MOL
|
||
| Formula |
C51H79NO13
|
|||
| Canonical SMILES |
CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)O)C)C)O)OC)C)C)C)OC
|
|||
| InChI |
1S/C51H79NO13/c1-30-16-12-11-13-17-31(2)42(61-8)28-38-21-19-36(7)51(60,65-38)48(57)49(58)52-23-15-14-18-39(52)50(59)64-43(33(4)26-37-20-22-40(53)44(27-37)62-9)29-41(54)32(3)25-35(6)46(56)47(63-10)45(55)34(5)24-30/h11-13,16-17,25,30,32-34,36-40,42-44,46-47,53,56,60H,14-15,18-24,26-29H2,1-10H3/b13-11+,16-12+,31-17+,35-25+/t30-,32-,33-,34-,36-,37+,38+,39+,40-,42+,43+,44-,46-,47+,51-/m1/s1
|
|||
| InChIKey |
QFJCIRLUMZQUOT-HPLJOQBZSA-N
|
|||
| CAS Number |
CAS 53123-88-9
|
|||
| PubChem Compound ID | ||||
| ChEBI ID |
CHEBI:9168
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | HUMAN mammalian target of rapamycin (mTOR) | Target Info | Inhibitor | [3] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | FDA Approved Drug Products from FDA Official Website. 2019. Application Number: (ANDA) 201578. | |||
| REF 2 | ClinicalTrials.gov (NCT04341675) Sirolimus Treatment in Hospitalized Patients With COVID-19 Pneumonia. U.S. National Institutes of Health. | |||
| REF 3 | Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2. Cell Discov. 2020 Mar 16;6:14. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.